These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11281812)

  • 21. [Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care].
    Espert R; Bertolín JM; Navarro JF; González A
    Rev Neurol; 1995; 23(119):86-95. PubMed ID: 8548650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug development in dementia.
    Cunningham EL; Passmore AP
    Maturitas; 2013 Nov; 76(3):260-6. PubMed ID: 23707728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease.
    Harkany T; Hortobágyi T; Sasvári M; Kónya C; Penke B; Luiten PG; Nyakas C
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):963-1008. PubMed ID: 10621945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Memantine hydrochloride in the treatment of dementia subtypes.
    Peng D; Yuan X; Zhu R
    J Clin Neurosci; 2013 Nov; 20(11):1482-5. PubMed ID: 24035650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapies for Alzheimer's disease.
    Melnikova I
    Nat Rev Drug Discov; 2007 May; 6(5):341-2. PubMed ID: 17539055
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current pharmacotherapy for Alzheimer's disease.
    Lleó A; Greenberg SM; Growdon JH
    Annu Rev Med; 2006; 57():513-33. PubMed ID: 16409164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel insights for the treatment of Alzheimer's disease.
    Kurz A; Perneczky R
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):373-9. PubMed ID: 20655969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Alzheimer disease.
    Winslow BT; Onysko MK; Stob CM; Hazlewood KA
    Am Fam Physician; 2011 Jun; 83(12):1403-12. PubMed ID: 21671540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
    Adlard PA; James SA; Bush AI; Masters CL
    Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on Alzheimer's Disease Therapy and Prevention Strategies.
    Graham WV; Bonito-Oliva A; Sakmar TP
    Annu Rev Med; 2017 Jan; 68():413-430. PubMed ID: 28099083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine.
    Desmidt T; Hommet C; Camus V
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):300-6. PubMed ID: 27651011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?
    Lockhart BP; Lestage PJ
    Exp Gerontol; 2003; 38(1-2):119-28. PubMed ID: 12543269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates.
    Viayna E; Sabate R; Muñoz-Torrero D
    Curr Top Med Chem; 2013; 13(15):1820-42. PubMed ID: 23931440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
    Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
    Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Nootropic drugs and their action mechanisms in relation to the neuropathobiology of senile dementia. I. Neurotransmission disorders in the brain].
    Benesová O
    Cesk Psychiatr; 1994 Aug; 90(4):191-200. PubMed ID: 7987928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cholesterol inhibitor and memantine in symptomatic dementia therapy].
    Rodda J; Carter J
    Praxis (Bern 1994); 2013 Feb; 102(5):293-300; discussion 298-9. PubMed ID: 23446240
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.